Faculty

Roland Walter

Adjunct Associate Professor, Epidemiology
Associate Professor, Medicine - Hematology
Adjunct Associate Professor, Laboratory Medicine and Pathology

206-667-3599
rwalter@fredhutch.org

Education

MD Medicine, University of Zurich (Switzerland), 1997
PhD Experimental Pathology, University of Washington, 2006
MS Epidemiology (Clinical Research), University of Washington, 2011

Contact

206-667-3599
rwalter@fredhutch.org

Fred Hutchinson Cancer Research Center
100 Fairview Ave. N., D2-190
Seattle, WA 98109
View Website »

Bio

My translational and clinical research program is focused on human acute leukemia, in particular acute myeloid leukemia (AML) but, more recently, also acute lymphoblastic leukemia (ALL). I am particularly interested in the preclinical and early clinical development of novel antigen-directed immunotherapies for acute leukemia and the delineation of the mechanisms of action and resistance that are relevant for these agents. Many of these studies are aimed at optimizing the use of CD33-targeted immunotherapy. We are also investigating the molecular and phenotypic characteristics of leukemia stem and progenitor cells to understand how antigen-directed immunotherapies can be best utilized to eliminate these cells. In clinical studies, I conduct trials testing novel treatments and innovative care approaches for acute leukemia patients. Furthermore, in collaborative research, I use large patient datasets to develop and improve diagnostic and prognostic tools in acute leukemia.  

Research Areas

Research Interests

  • Acute myeloid leukemia
  • CD33
  • Immunotherapy of AML
  • Clinical trials in AM
  • Measurable residual disease (MRD)
  • Predictive modeling

Recent Publications (PubMed)

Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection.
(2021 May 5)
Transplant Cell Ther
Ford ES, Duke ER, Cheng GS, Yoke LM, Liu C, Hill JA, Pergam SA, Pipavath SNJ, Walter RB, Mielcarek M, Schiffer JT, Boeckh M

Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
(2021 Jun)
Leukemia 35(6): 1529-1538
Walter RB, Ofran Y, Wierzbowska A, Ravandi F, Hourigan CS, Ngai LL, Venditti A, Buccisano F, Ossenkoppele GJ, Roboz GJ

Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML).
(2021 Jun)
Leuk Lymphoma 62(6): 1532-1535
Hochman MJ, Othus M, Walter RB, Shaw C, Gardner K, Percival MM, Halpern AB, Hendrie PC, Sandmaier BM, Estey EH

The evolving use of gemtuzumab ozogamicin in acute myeloid leukemia.
(2021 Mar)
Clin Adv Hematol Oncol 19(3): 152-154
Walter RB

Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
(2021 Feb 15)
Leukemia
Godwin CD, Laszlo GS, Fiorenza S, Garling EE, Phi TD, Bates OM, Correnti CE, Hoffstrom BG, Lunn MC, Humbert O, Kiem HP, Turtle CJ, Walter RB

Show complete publication list

In the News

No news articles at this time.